MARK VOLPE: Open Payments
NPI 1720452527 · SUFFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,005 in 241 payments from 35 companies in 2025. Trend: 2023 $4,364 · 2024 $4,100 · 2025 $5,005
Food & beverage: $5,005
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 62 | $881 |
| AstraZeneca Pharmaceuticals LP | 28 | $613 |
| PFIZER INC. | 22 | $344 |
| Novo Nordisk Inc | 12 | $237 |
| Teva Pharmaceuticals USA, Inc. | 9 | $203 |
| Amgen Inc. | 9 | $192 |
| Madrigal Pharmaceuticals | 2 | $173 |
| Lundbeck LLC | 6 | $171 |
| Abbott Laboratories | 7 | $157 |
| Azurity Pharmaceuticals, Inc. | 8 | $154 |
Products named: VRAYLAR, AIRSUPRA, UBRELVY, AUSTEDO XR, EVENITY, REZDIFFRA, VYEPTI, BREZTRI.
Industry payments across CT — which companies pay providers there.
